Researchers Linked Enzyme Expression to Gastric Cancer
A study identified a specific tumor cell population that helps gastric cancer evade immune responses.
Updated on Oct. 14, 2026 in Cancer
Researchers have identified a population of gastric cancer tumor cells with high ADA2 expression that correlates with poor patient prognosis. These cells secrete inosine, which actively modulates the tumor microenvironment to weaken antitumor immunity.
Why it matters
Understanding how tumor-derived metabolites influence the immune system is crucial for developing better cancer treatments. By identifying this specific axis, researchers have revealed a new potential target for gastric cancer immunotherapy.
The study utilized gastric cancer models to determine that high ADA2 expression leads to poor patient outcomes. This research establishes the inosine-MAT2A-SAM axis as a significant regulatory mechanism in tumor growth.
The details
The process involves tumor cells secreting inosine, which upregulates MAT2A expression and acts as a carbon source for S-adenosylmethionine (SAM) synthesis. High SAM levels increase global methylation, ultimately driving the M2 polarization of tumor-associated macrophages to suppress antitumor immunity.
Timeline
October 14, 2026: Article publication date.
The Big Picture
This discovery marks a shift in the ongoing development of tumor microenvironment-targeted cancer immunotherapies by identifying the inosine-MAT2A-SAM axis. It moves beyond standard treatment models to address how specific tumor metabolites actively reprogram immune cells.
This research provides a new foundation for developing future drugs that specifically target the identified inosine-MAT2A-SAM axis in gastric cancer patients. While not an immediate clinical treatment, the findings may influence the design of future personalized immunotherapy strategies.
The takeaway
Targeting metabolic pathways like the inosine-MAT2A-SAM axis offers a promising route for improving cancer survival rates. Future clinical focus will likely center on therapies that inhibit these specific metabolite-driven immune interactions.
Further reading
For more information on current treatment trends, see our Cancer section.
More information
View the full details in the peer-reviewed gastric cancer research study.
Source note: This article includes information reported by Nature.
